ST
Sidewinder Therapeutics
United States · Biotech
Develops next-generation bispecific ADCs for cancer treatment
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $137M | Alexandria Real Estate Equities — Role not disclosedAstellas Venture Management — Role not disclosedDCVC Bio — Role not disclosedFrazier Life Sciences — Role not disclosedGoldman Sachs Alternatives Life Sciences — Role not disclosedLongwood Fund — Role not disclosedNovartis Venture Fund — Role not disclosedOrbiMed — Role not disclosedSamsara BioCapital — Role not disclosed |